2024
DOI: 10.3389/fneur.2024.1395413
|View full text |Cite
|
Sign up to set email alerts
|

Practical use of DAT SPECT imaging in diagnosing dementia with Lewy bodies: a US perspective of current guidelines and future directions

Deirdre M. O’Shea,
Alexander Arkhipenko,
Douglas Galasko
et al.

Abstract: BackgroundDiagnosing Dementia with Lewy Bodies (DLB) remains a challenge in clinical practice. The use of 123I-ioflupane (DaTscan™) SPECT imaging, which detects reduced dopamine transporter (DAT) uptake—a key biomarker in DLB diagnosis—could improve diagnostic accuracy. However, DAT imaging is underutilized despite its potential, contributing to delays and suboptimal patient management.MethodsThis review evaluates DLB diagnostic practices and challenges faced within the U.S. by synthesizing information from cu… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2024
2024
2024
2024

Publication Types

Select...
3

Relationship

0
3

Authors

Journals

citations
Cited by 3 publications
(1 citation statement)
references
References 111 publications
0
1
0
Order By: Relevance
“… 4 One reason hindering proper diagnosis is the limited awareness and knowledge of DLB among primary care physicians, thus failing to make appropriate referrals to specialists. 4 , 5 , 6 Additionally, the limited availability of established biomarkers for DLB, 7 coupled with invasive and expensive standard biomarkers for AD, 8 further hinders proper identification. Therefore, a screening tool capable of suggesting the possibility of DLB, even in nonspecialist settings, would facilitate timely referrals to specialists and enable early differential diagnosis of DLB.…”
Section: Introductionmentioning
confidence: 99%
“… 4 One reason hindering proper diagnosis is the limited awareness and knowledge of DLB among primary care physicians, thus failing to make appropriate referrals to specialists. 4 , 5 , 6 Additionally, the limited availability of established biomarkers for DLB, 7 coupled with invasive and expensive standard biomarkers for AD, 8 further hinders proper identification. Therefore, a screening tool capable of suggesting the possibility of DLB, even in nonspecialist settings, would facilitate timely referrals to specialists and enable early differential diagnosis of DLB.…”
Section: Introductionmentioning
confidence: 99%